Antiviral for the treatment of covid has shown high efficacy – Human – Science and Technology

The American pharmaceutical company Pfizer announced on Friday that its drug for the treatment of the COVID-19 disease had proved very high in clinical trials in preventing hospitalizations and deaths.

According to the company, the drug called Paxlovid can reduce the risk of hospitalization and eventual death by up to 89 percent in patients with covid, who are at high risk of severe disease.

“These data suggest that if we develop an oral antiviral drug approved by regulators, it has the potential to save the lives of patients with covid, reduce the severity of COVID-19 infection and prevent up to nine out of ten hospitalizations,” said Pfizer CEO Albert Bourla.

According to him, the results of the clinical study were even so convincing at a later stage that Pfizer stopped adding new volunteers to the study. The company plans to submit the data to the US Food and Drug Administration (FDA) as soon as possible. “Today is a real turning point in the global effort to stop the trigger caused by the pandemic,” Bourla commented on the release of the results of Paxlovid’s clinical trials.

Read also Delta plus has already been confirmed in Slovakia

The drug from Pfizer is the second prospective oral antiviral drug after a drug from Merck, which was conditionally approved for use by Britain on Thursday, as the first country in the world.


Source: Pravda – Veda a technika by vat.pravda.sk.

*The article has been translated based on the content of Pravda – Veda a technika by vat.pravda.sk. If there is any problem regarding the content, copyright, please leave a report below the article. We will try to process as quickly as possible to protect the rights of the author. Thank you very much!

*We just want readers to access information more quickly and easily with other multilingual content, instead of information only available in a certain language.

*We always respect the copyright of the content of the author and always include the original link of the source article.If the author disagrees, just leave the report below the article, the article will be edited or deleted at the request of the author. Thanks very much! Best regards!